M e d i c i n e A v e 2 PROLASTIISr Ta[ecris 1. AGENCY: DraftFCB Healthcare CREATIVE TEAM: Tim Hawkey, Ken Zierler, Frank Roes, Joan Larson CLIENT: Talecris 2. AGENCY: Robert A. Becker CREATIVE TEAM: Jerry Fox, Malcolm Hall CLIENT: Centocor 3. AGENCY: Pacific Com. CREATIVE TEAM: Ron Ovadia, Doug Newbry, Larry Dennis, Nancy Benton, Jo Tradii CLIENT: Allergan BEGINS WITH HET/W/ASE — 15 more patients out Of 100 achieved complete reperfusion (TIMI3 How) with RETAVASE at 90 minutes than with alteplase. The correlation between patency and patient outcome has not been established Fast, convenient double-bolus dosing, complete in 30 minutes As with all thrombolytic agents. RETAVASE therapy increases the risk of bleeding, including intracranial bleeding, and should be used only in appropriate patients. In addition, thrombolytic therapy increases the absolute risk ot stroke, including hemorrhagic stroke, in patients of advanced age. 'resenting Intanutoo at Or t 212
RkJQdWJsaXNoZXIy NDMwNDAx